Prominent genomics results include the 17q21 locus, HHIP and MUC5B genetic variants that confer risk for asthma, COPD and IPF, respectively, while prominent transcriptomic results include the differential expression of bitter taste receptor and KLF5 genes observed in asthma that may lead to novel therapeutic targets. This evidence concerns the gene MUC5B and idiopathic interstitial pneumonia.